Sophiris Bio (SPHS) 10-Q 13 Nov 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 08, 2018
Document Information [Line Items]
Entity Registrant Name	SOPHIRIS BIO INC.
Entity Central Index Key	1,563,855
Trading Symbol	sphs
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		30,111,153
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Ex Transition Period	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 12,048	$ 16,087
Securities available-for-sale	2,498	9,757
Prepaid expenses and other current assets	888	1,012
Total current assets	15,434	26,856
Property and equipment, net	4	2
Other long-term assets		19
Total assets	15,438	26,877
Current liabilities:
Accounts payable	400	832
Accrued expenses	2,098	1,499
Current portion of promissory note	1,212	372
Total current liabilities	3,710	2,703
Long-term promissory note	5,751	6,435
Warrant liability	9,946	10,089
Total liabilities	19,407	19,227
Commitments and contingencies
Shareholders’ (deficit) equity:
Common shares, unlimited authorized shares, no par value; 30,111,153 shares issued and outstanding at September 30, 2018 and December 31, 2017	131,247	131,247
Contributed surplus	26,531	25,854
Accumulated other comprehensive gain	99	97
Accumulated deficit	(161,846)	(149,548)
Total shareholders’ (deficit) equity	(3,969)	7,650
Total liabilities and shareholders’ (deficit) equity	$ 15,438	$ 26,877

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	Sep. 30, 2018	Dec. 31, 2017
Common shares, par value (in dollars per share)	$ 0	$ 0
Common shares, shares issued (in shares)	30,111,153	30,111,153
Common shares, shares outstanding (in shares)	30,111,153	30,111,153

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating expenses:
Research and development	$ 1,798	$ 1,649	$ 8,718	$ 4,244
General and administrative	1,155	1,685	3,494	4,422
Total operating expenses	2,953	3,334	12,212	8,666
Other income (expense):
Interest expense	(173)	(35)	(514)	(35)
Interest income	80	56	258	159
Gain on revaluation of warrant liability	153	670	143	3,905
Other income (expense), net	21	(11)	27	(27)
Total other income (expense)	81	680	(86)	4,002
Net loss	$ (2,872)	$ (2,654)	$ (12,298)	$ (4,664)
Basic and diluted loss per share (in dollars per share)	$ (0.10)	$ (0.09)	$ (0.41)	$ (0.15)
Weighted average number of outstanding shares – basic and diluted (in shares)	30,111	30,111	30,111	30,111
Other comprehensive loss:
Unrealized income (loss) on securities available-for-sale	$ 2	$ 11	$ 2	$ (3)
Total other comprehensive loss	$ (2,870)	$ (2,643)	$ (12,296)	$ (4,667)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows used in operating activities
Net loss	$ (12,298)	$ (4,664)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	677	1,328
Accretion of debt discount	113	7
Amortization of promissory note issuance costs	43	3
Depreciation of property and equipment	2	4
Amortization of (premium)/discount on securities available-for-sale	(44)	119
Change in fair value warrant liability	(143)	(3,905)
Foreign exchange transaction loss		1
Changes in operating assets and liabilities:
Prepaid expenses and other assets	143	(187)
Accounts payable	(433)	254
Accrued expenses	599	(278)
Net cash used in operating activities	(11,341)	(7,318)
Cash flows provided by investing activities
Purchases of property and equipment	(4)	(3)
Maturities of securities available-for-sale	9,387	12,736
Purchases of securities available-for-sale	(2,081)	(8,683)
Net cash provided by investing activities	7,302	4,050
Cash flows provided by financing activities
Proceeds from exercise of stock options		2
Proceeds from the issuance of the Silicon Valley Bank promissory note, net of issuance cost		6,953
Net cash provided by financing activities		6,955
Effect of exchange rate changes on cash and cash equivalents		(1)
Net (decrease) increase in cash and cash equivalents	(4,039)	3,686
Cash and cash equivalents at beginning of period	16,087	12,800
Cash and cash equivalents at end of period	12,048	16,486
Supplemental disclosures of non-cash investing and financing activities:
Change in the fair value of stock-based compensation liability recorded to contributed surplus		(57)
Valuation of warrants issued in connection with the Silicon Valley Bank promissory note		185
Issuance costs included in accounts payable and accrued expenses but not paid		$ 23

Note 1 - Nature of the Business

Note 1 - Nature of the Business	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Nature of Operations [Text Block]	1. Nature of the business Company Sophiris Bio Inc., or the Company, or Sophiris, is a clinical-stage biopharmaceutical company focused on innovative products for the treatment of urological diseases. The Company is governed by the British Columbia Business Corporations Act. The Company’s operations were initially located in Vancouver, British Columbia until April 2011, The condensed consolidated financial statements include the accounts of Sophiris Bio Inc. and its wholly-owned subsidiaries, Sophiris Bio Corp. and Sophiris Bio Holding Corp., both of which are incorporated in the State of Delaware. Liquidity The condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business. At September 30, 2018, $14.5 June 2019 one The Company is currently evaluating options to further advance the clinical development of topsalysin. The Company will require significant additional funding to advance topsalysin in clinical development. The Company could use dilutive funding options such as an equity financing and/or non-dilutive funding options such as a partnering arrangement or royalty agreement to fund future clinical development of topsalysin. At this point in time the Company does not 3 second 3 no If the Company is unable to raise additional capital to fund its development program efforts beyond its ongoing clinical trial in sufficient amounts or on terms acceptable to it, the Company may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of significant accounting policies Basis of consolidation The condensed consolidated financial statements include the accounts of the Company, Sophiris Bio Corp. and Sophiris Bio Holding Corp. All intercompany balances and transactions have been eliminated for purposes of consolidation. Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, for the interim financial information and the rules and regulations of the Securities and Exchange Commission, or SEC, related to quarterly reports on Form 10 not 10 March 21, 2018. not not may During the nine September 30, 2018, no December 31, 2017, Revenue recognition Effective January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 606 The Company may may 606. The Company will then perform an analysis to determine the total transaction price that the Company expects to receive from satisfying the performance obligations in the agreement. To the extent that the agreement includes variable consideration, amounts which can vary depending on the occurrence or nonoccurrence of a future event, the amount included in the total transaction price may not not The calculated transaction price will then be allocated to the separate performance obligations based upon the relative standalone selling price of the performance obligations. If standalone selling price cannot be determined, a residual approach may For each performance obligation, the Company must determine the period over which the performance obligations will be satisfied, and revenue recognized. Revenue will be recognized over time if the Company satisfies the performance obligation over a period of time whereas revenue will be recognized at a point in time if the performance obligation is satisfied at a specific point in time. Revenue related to the transfer of an intellectual property license will be recognized either upon the transfer of the license or over a period of time depending upon whether or not not may Recent accounting pronouncements In February 2016, No. 2016 02, Leases (Topic 842 July 2018 No. 2018 11. not December 15, 2018 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 eight first 2018, not In May 2017, No. 2017 09, Compensation-Stock Compensation (Topic 718 , 2017 09. 718. first 2018, not

Note 3 - Net Loss Per Common Sh

Note 3 - Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	3. Net loss per common share Basic net loss per share is calculated by dividing the net loss attributable to common shareholders by the weighted-average number of common shares outstanding during the period, without consideration for common shares equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common shareholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. The following diluted securities have been excluded from the computation of diluted weighted-average shares outstanding as of September 30, 2018 2017 September 30, 2018 2017 Options to purchase common shares 2,940 2,888 Common share purchase warrants 5,798 5,825

Note 4 - Securities Available-f

Note 4 - Securities Available-for-sale	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	4. Securities Available-for-Sale Securities available-for-sale consisted of the following as of September 30, 2018 ( September 30, 2018 Amortized Unrealized Estimated Cost Gain Loss Fair Value Commercial paper $ 999 $ — $ — $ 999 U.S. government sponsored enterprise securities 1,499 — — 1,499 $ 2,498 $ — $ — $ 2,498 As of September 30, 2018, one Securities available-for-sale consisted of the following as of December 31, 2017 December 31, 2017 Amortized Unrealized Estimated Cost Gain Loss Fair Value Commercial paper $ 3,590 $ — $ — $ 3,590 U.S. government sponsored enterprise securities 4,985 — (2 ) 4,983 Corporate debt securities 1,184 — — 1,184 $ 9,759 $ — $ (2 ) $ 9,757 As of December 31, 2017, one

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurement and Financial Instruments	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	5. Fair value measurement and financial instruments As of September 30, 2018, $14.2 two two two 1 2 2 third 3 The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2018 December 31, 2017 ( September 30, 2018 Level 1 Level 2 Level 3 Assets: Money market funds $ 28 $ 28 $ — $ — Commercial paper 11,743 — 11,743 — U.S. government sponsored enterprise securities 2,399 — 2,399 — Total assets $ 14,170 $ 28 $ 14,142 $ — Liabilities: Warrant liability $ 9,946 $ — $ — $ 9,946 Total liabilities $ 9,946 $ — $ — $ 9,946 December 31, 2017 Level 1 Level 2 Level 3 Assets: Money market funds $ 34 $ 34 $ — $ — Commercial paper 19,020 — 19,020 — U.S. government sponsored enterprise securities 4,983 — 4,983 — Corporate debt securities 1,184 — 1,184 — Total assets $ 25,221 $ 34 $ 25,187 $ — Liabilities: Warrant liability $ 10,089 $ — $ — $ 10,089 Total liabilities $ 10,089 $ — $ — $ 10,089 Warrant liability In connection with the offering completed on May 11, 2016, 1,785,714 may May 11, 2016, September 30, 2018, 10,000 May 11, 2016 September 30, 2018. September 30, 2018 December 31, 2017 Stock price $ 2.79 $ 2.27 Exercise price $ 1.40 $ 1.40 Risk-free interest rate 2.83 % 2.01 % Volatility 97.81 % 143.57 % Dividend yield 0.00 % 0.00 % Expected life in years 2.61 3.36 Calculated fair value per warrant $ 2.01 $ 1.95 In connection with the offering completed on August 26, 2016, 5,606,250 may August 26, 2016, September 30, 2018, September 30, 2018. September 30, 2018 December 31, 2017 Stock price $ 2.79 $ 2.27 Exercise price $ 4.00 $ 4.00 Risk-free interest rate 2.85 % 2.04 % Volatility 116.80 % 145.36 % Dividend yield 0.00 % 0.00 % Expected life in years 2.9 3.65 Calculated fair value per warrant $ 1.77 $ 1.80 The following table presents a reconciliation of the warrant liability measured at fair value using unobservable inputs (Level 3 Warrant Liability Liabilities: Balance at January 1, 2018 $ 10,089 Change in the fair value of warrant liability (143 ) Balance at September 30, 2018 $ 9,946 The Company recognizes transfers into and out of levels within the fair value hierarchy at the end of the reporting period in which the actual event or change in circumstances that caused the transfer occurs. There were no

Note 6 - Prepaid Expenses and O

Note 6 - Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Prepaid Expenses and Other Assets [Text Block]	6. Prepaid expense s and other current assets Prepaid expenses and other current assets as of September 30, 2018 December 31, 2017 September 30, 2018 December 31, 2017 Prepaid insurance $ 343 $ 233 Prepaid research and development expenses 439 709 Other prepaid expenses 106 70 Prepaid expenses and other current assets $ 888 $ 1,012 As of September 30, 2018 December 31, 2017, $0.4 $0.7 third

Note 7 - Accrued Expenses

Note 7 - Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued expenses Accrued expenses as of September 30, 2018 December 31, 2017 September 30, 2018 December 31, 2017 Accrued personnel related costs $ 434 $ 904 Accrued interest 39 41 Accrued research and development expenses 1,377 273 Accrued audit and tax services 225 246 Other accrued expenses 23 35 Accrued expenses $ 2,098 $ 1,499

Note 8 - Promissory Notes

Note 8 - Promissory Notes	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Promissory notes On September 8, 2017, two first $7.0 second not $3.0 $20.0 December 31, 2018 2b December 31, 2018. The principal borrowed under the first $7.0 6.75% 1% 3% September 1, 2021, 5% $7.0 In September 2018, March 31, 2019. April 1, 2019 September 1, 2021. Pursuant to the first 99,526 $2.11 seven $0.2 1.9%, 113.9%, 0% 7. $7.0 September 30, 2017, 3 $7.0 The third $0.1 In connection with the loan, the Company granted to Silicon Valley Bank a security interest in all of the Company’s personal property now owned or hereafter acquired, excluding intellectual property and certain other assets. The Company is not September 30, 2018, may As of September 30, 2018, 2019 $ 2,100 2020 2,800 2021 2,450 Total $ 7,350 The following table shows actual interest expense, amortization of the debt discount and amortization of the issuance costs that was charged to interest expense (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Simple interest $ 121 $ 25 $ 358 $ 25 Accretion of debt discount 38 7 113 7 Amortization of promissory note issuance costs 14 3 43 3 Total $ 173 $ 35 $ 514 $ 35 The Company calculated the fair value of the secured promissory notes as $6.8 3 September 30, 2018. 6.75%,

Note 9 - Revenue for License Ag

Note 9 - Revenue for License Agreement	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Collaborative Arrangement Disclosure [Text Block]	9. Revenue for license agreement In April 2010, Pursuant to the agreement in 2010, $3.0 $72.0 $17.0 $5.0 $7.0 $5.0 $21.0 $7.0 $7.0 $7.0 $21.0 $7.0 $7.0 $7.0 $13.0 not $5.0 $8.0 may 20 29% Accounting for the Kissei Agreement prior to the Adoption of ASC Topic 606: The Company recognized the entire $3.0 2010. December 31, 2013, $5.0 No Accounting for the Kissei Agreement after the Adoption of Topic 606: Effective January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 The Company has reviewed its agreement with Kissei and determined that Kissei met the definition of a customer as defined in Topic 606. The Company determined that the license provided to Kissei represents a right to use functional intellectual property. This determination is based upon Kissei’s ability to use the license as soon as it was granted and that the Company has no not no no $3.0 2010. As outlined above the agreement also includes development and sales-based milestone payments and sales-based royalties. Upon the signing of the agreement, the development based milestone payments would have been considered variable consideration under Topic 606 third not no may no $5.0 December 31, 2013 606 no $5.0 2013. Topic 606 not no no Based on the above, the Company’s adoption of Topic 606 not no 606.

Note 10 - Stock-based Compensat

Note 10 - Stock-based Compensation Plan	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. Stock-based compensation plan The Company’s Amended and Restated 2011 As of September 30, 2018, 71,000 The Company recognized stock-based compensation expense as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development $ 38 $ 121 $ 142 $ 376 General and administrative 219 340 535 952 Total $ 257 $ 461 $ 677 $ 1,328 As of September 30, 2018 $0.4 ten The following table summarizes stock option activity, including options issued to employees, directors and non-employees (in thousands, except per share): Options Weighted Average Outstanding at January 1, 2018 2,931 $ 3.10 Options granted 80 2.91 Options expired (71 ) 13.16 Outstanding at September 30, 2018 2,940 $ 2.85 The total amount of options expired for the nine September 30, 2018 The fair values of options granted during the nine September 30, 2018 2017 Nine Months Ended September 30, 2018 2017 Expected life of the option term (years) 4.7 4.1 Risk-free interest rate 2.67 % 1.61 % Dividend rate 0 % 0 % Volatility 126.2 % 144.8 %

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Commitments and contingencies Purchase commitments The Company is required to schedule certain manufacturing activities in advance. If the Company cancels any of these scheduled activities without proper notice the Company could be required to pay penalties of 50% 100% $1.0 September 30, 2018 The amounts recorded for these manufacturing contracts, which are included as a component of research and development expense, were $0.7 $0.1 three September 30, 2018 2017, $4.3 $0.2 nine September 30, 2018 2017,

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of consolidation The condensed consolidated financial statements include the accounts of the Company, Sophiris Bio Corp. and Sophiris Bio Holding Corp. All intercompany balances and transactions have been eliminated for purposes of consolidation.
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States, or GAAP, for the interim financial information and the rules and regulations of the Securities and Exchange Commission, or SEC, related to quarterly reports on Form 10 not 10 March 21, 2018. not not may During the nine September 30, 2018, no December 31, 2017,
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition Effective January 1, 2018, No. 2014 09, Revenue from Contracts with Customers (Topic 606 606 The Company may may 606. The Company will then perform an analysis to determine the total transaction price that the Company expects to receive from satisfying the performance obligations in the agreement. To the extent that the agreement includes variable consideration, amounts which can vary depending on the occurrence or nonoccurrence of a future event, the amount included in the total transaction price may not not The calculated transaction price will then be allocated to the separate performance obligations based upon the relative standalone selling price of the performance obligations. If standalone selling price cannot be determined, a residual approach may For each performance obligation, the Company must determine the period over which the performance obligations will be satisfied, and revenue recognized. Revenue will be recognized over time if the Company satisfies the performance obligation over a period of time whereas revenue will be recognized at a point in time if the performance obligation is satisfied at a specific point in time. Revenue related to the transfer of an intellectual property license will be recognized either upon the transfer of the license or over a period of time depending upon whether or not not may
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements In February 2016, No. 2016 02, Leases (Topic 842 July 2018 No. 2018 11. not December 15, 2018 In August 2016, 2016 15, Statement of Cash Flows (Topic 230 eight first 2018, not In May 2017, No. 2017 09, Compensation-Stock Compensation (Topic 718 , 2017 09. 718. first 2018, not

Note 3 - Net Loss Per Common _2

Note 3 - Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	September 30, 2018 2017 Options to purchase common shares 2,940 2,888 Common share purchase warrants 5,798 5,825

Note 4 - Securities Available_2

Note 4 - Securities Available-for-sale (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Available-for-sale Securities [Table Text Block]	September 30, 2018 Amortized Unrealized Estimated Cost Gain Loss Fair Value Commercial paper $ 999 $ — $ — $ 999 U.S. government sponsored enterprise securities 1,499 — — 1,499 $ 2,498 $ — $ — $ 2,498 December 31, 2017 Amortized Unrealized Estimated Cost Gain Loss Fair Value Commercial paper $ 3,590 $ — $ — $ 3,590 U.S. government sponsored enterprise securities 4,985 — (2 ) 4,983 Corporate debt securities 1,184 — — 1,184 $ 9,759 $ — $ (2 ) $ 9,757

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurement and Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	September 30, 2018 Level 1 Level 2 Level 3 Assets: Money market funds $ 28 $ 28 $ — $ — Commercial paper 11,743 — 11,743 — U.S. government sponsored enterprise securities 2,399 — 2,399 — Total assets $ 14,170 $ 28 $ 14,142 $ — Liabilities: Warrant liability $ 9,946 $ — $ — $ 9,946 Total liabilities $ 9,946 $ — $ — $ 9,946 December 31, 2017 Level 1 Level 2 Level 3 Assets: Money market funds $ 34 $ 34 $ — $ — Commercial paper 19,020 — 19,020 — U.S. government sponsored enterprise securities 4,983 — 4,983 — Corporate debt securities 1,184 — 1,184 — Total assets $ 25,221 $ 34 $ 25,187 $ — Liabilities: Warrant liability $ 10,089 $ — $ — $ 10,089 Total liabilities $ 10,089 $ — $ — $ 10,089
Warrant Liability [Member]
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	September 30, 2018 December 31, 2017 Stock price $ 2.79 $ 2.27 Exercise price $ 1.40 $ 1.40 Risk-free interest rate 2.83 % 2.01 % Volatility 97.81 % 143.57 % Dividend yield 0.00 % 0.00 % Expected life in years 2.61 3.36 Calculated fair value per warrant $ 2.01 $ 1.95 September 30, 2018 December 31, 2017 Stock price $ 2.79 $ 2.27 Exercise price $ 4.00 $ 4.00 Risk-free interest rate 2.85 % 2.04 % Volatility 116.80 % 145.36 % Dividend yield 0.00 % 0.00 % Expected life in years 2.9 3.65 Calculated fair value per warrant $ 1.77 $ 1.80
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant Liability Liabilities: Balance at January 1, 2018 $ 10,089 Change in the fair value of warrant liability (143 ) Balance at September 30, 2018 $ 9,946

Note 6 - Prepaid Expenses and_2

Note 6 - Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Prepaid Expense and Other Current Assets [Table Text Block]	September 30, 2018 December 31, 2017 Prepaid insurance $ 343 $ 233 Prepaid research and development expenses 439 709 Other prepaid expenses 106 70 Prepaid expenses and other current assets $ 888 $ 1,012

Note 7 - Accrued Expenses (Tabl

Note 7 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	September 30, 2018 December 31, 2017 Accrued personnel related costs $ 434 $ 904 Accrued interest 39 41 Accrued research and development expenses 1,377 273 Accrued audit and tax services 225 246 Other accrued expenses 23 35 Accrued expenses $ 2,098 $ 1,499

Note 8 - Promissory Notes (Tabl

Note 8 - Promissory Notes (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	2019 $ 2,100 2020 2,800 2021 2,450 Total $ 7,350
Contractual Interest Expense and Amortization of Debt Issuance Costs and Debt Discount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Simple interest $ 121 $ 25 $ 358 $ 25 Accretion of debt discount 38 7 113 7 Amortization of promissory note issuance costs 14 3 43 3 Total $ 173 $ 35 $ 514 $ 35

Note 10 - Stock-based Compens_2

Note 10 - Stock-based Compensation Plan (Tables)	9 Months Ended
	Sep. 30, 2018
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Research and development $ 38 $ 121 $ 142 $ 376 General and administrative 219 340 535 952 Total $ 257 $ 461 $ 677 $ 1,328
Share-based Compensation, Stock Options, Activity [Table Text Block]	Options Weighted Average Outstanding at January 1, 2018 2,931 $ 3.10 Options granted 80 2.91 Options expired (71 ) 13.16 Outstanding at September 30, 2018 2,940 $ 2.85
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2018 2017 Expected life of the option term (years) 4.7 4.1 Risk-free interest rate 2.67 % 1.61 % Dividend rate 0 % 0 % Volatility 126.2 % 144.8 %

Note 1 - Nature of the Busine_2

Note 1 - Nature of the Business (Details Textual) $ in Millions	Sep. 30, 2018USD ($)
Cash, Cash Equivalents and Available-for-sale Securities	$ 14.5

Note 3 - Net Loss Per Common _3

Note 3 - Net Loss Per Common Share - Potentially Dilutive Securities Excluded From Diluted Weighted-average Shares Outstanding (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Employee Stock Option [Member]
Anti-dilutive securities excluded from computation of weighted-average shares outstanding (in shares)	2,940	2,888
Warrant [Member]
Anti-dilutive securities excluded from computation of weighted-average shares outstanding (in shares)	5,798	5,825

Note 4 - Securities Available_3

Note 4 - Securities Available-for-sale - Securities Available-for-sale (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Amortized Cost	$ 2,498	$ 9,759
Unrealized Gain
Unrealized Loss		(2)
Estimated Fair Value	2,498	9,757
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Amortized Cost	999	3,590
Unrealized Gain
Unrealized Loss
Estimated Fair Value	999	3,590
US Government-sponsored Enterprises Debt Securities [Member]
Amortized Cost	1,499	4,985
Unrealized Gain
Unrealized Loss		(2)
Estimated Fair Value	$ 1,499	4,983
Corporate Debt Securities [Member]
Amortized Cost		1,184
Unrealized Gain
Unrealized Loss
Estimated Fair Value		$ 1,184

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurement and Financial Instruments (Details Textual) - USD ($) $ in Thousands	Aug. 26, 2016	May 11, 2016	Sep. 30, 2018	Dec. 31, 2017
Class of Warrant or Right, Issued During Period		1,785,714
Warrants, Issued on May 11, 2016 [Member]
Class of Warrant or Right, Outstanding			10,000
Warrants, Issued on August 26, 2016 [Member]
Class of Warrant or Right, Issued During Period	5,606,250
Fair Value, Measurements, Recurring [Member]
Assets, Fair Value Disclosure			$ 14,170	$ 25,221

Note 5 - Fair Value Measureme_4

Note 5 - Fair Value Measurement and Financial Instruments - Assets and Liabilities Measured at Fair Value Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt securities available-for-sale	$ 2,498	$ 9,757
US Government-sponsored Enterprises Debt Securities [Member]
Debt securities available-for-sale	1,499	4,983
Corporate Debt Securities [Member]
Debt securities available-for-sale		1,184
Fair Value, Measurements, Recurring [Member]
Commercial paper	11,743	19,020
Total assets	14,170	25,221
Total liabilities	9,946	10,089
Fair Value, Measurements, Recurring [Member] | Warrant Liability [Member]
Warrant liability	9,946	10,089
Fair Value, Measurements, Recurring [Member] | US Government-sponsored Enterprises Debt Securities [Member]
Debt securities available-for-sale	2,399	4,983
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Debt securities available-for-sale		1,184
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Commercial paper
Total assets	28	34
Total liabilities
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Warrant Liability [Member]
Warrant liability
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government-sponsored Enterprises Debt Securities [Member]
Debt securities available-for-sale
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]
Debt securities available-for-sale
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Commercial paper	11,743	19,020
Total assets	14,142	25,187
Total liabilities
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Warrant Liability [Member]
Warrant liability
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government-sponsored Enterprises Debt Securities [Member]
Debt securities available-for-sale	2,399	4,983
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]
Debt securities available-for-sale		1,184
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Commercial paper
Total assets
Total liabilities	9,946	10,089
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Warrant liability	9,946	10,089
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government-sponsored Enterprises Debt Securities [Member]
Debt securities available-for-sale
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]
Debt securities available-for-sale
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Money market funds	28	34
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Money market funds	28	34
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Money market funds
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Money market funds

Note 5 - Fair Value Measureme_5

Note 5 - Fair Value Measurement and Financial Instruments - Fair Value Assumptions, Warrant Liability (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018yr$ / shares	Dec. 31, 2017yr$ / shares
Warrants, Issued on May 11, 2016 [Member]
Calculated fair value per warrant (in dollars per share) | $ / shares	$ 2.01	$ 1.95
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	2.79	2.27
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	1.4	1.4
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0283	0.0201
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.9781	1.4357
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Warrants, Issued on May 11, 2016 [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	2.61	3.36
Warrants, Issued on August 26, 2016 [Member]
Calculated fair value per warrant (in dollars per share) | $ / shares	$ 1.77	$ 1.80
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Share Price [Member]
Warrants and Rights Outstanding, Measurement Input	2.79	2.27
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Exercise Price [Member]
Warrants and Rights Outstanding, Measurement Input	4	4
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0285	0.0204
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.168	1.4536
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Warrants, Issued on August 26, 2016 [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	2.9	3.65

Note 5 - Fair Value Measureme_6

Note 5 - Fair Value Measurement and Financial Instruments - Fair Value Reconciliation of Warrant Liability (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Change in fair value warrant liability	$ (143)	$ (3,905)
Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Balance	10,089
Change in fair value warrant liability	(143)
Balance	$ 9,946

Note 6 - Prepaid Expenses and_3

Note 6 - Prepaid Expenses and Other Current Assets (Details Textual) - USD ($) $ in Millions	Sep. 30, 2018	Dec. 31, 2017
Upfront Fees Included in Prepaid Researchs and Development Expenses	$ 0.4	$ 0.7

Note 6 - Prepaid Expenses and_4

Note 6 - Prepaid Expenses and Other Current Assets - Components of Prepaid Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Prepaid insurance	$ 343	$ 233
Prepaid research and development expenses	439	709
Other prepaid expenses	106	70
Prepaid expenses and other current assets	$ 888	$ 1,012

Note 7 - Accrued Expenses - Com

Note 7 - Accrued Expenses - Components of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accrued personnel related costs	$ 434	$ 904
Accrued interest	39	41
Accrued research and development expenses	1,377	273
Other accrued expenses	23	35
Accrued expenses	2,098	1,499
Accrued Audit and Tax Services [Member]
Accrued audit and tax services	$ 225	$ 246

Note 8 - Promissory Notes (Deta

Note 8 - Promissory Notes (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Sep. 08, 2017	Sep. 30, 2018	Sep. 30, 2017
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	99,526
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.11
Warrants Expiration Period	7 years
Warrants and Rights Outstanding	$ 0.2
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.019
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	1.139
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0
Warrants Issued in Connection with First Tranche Loan with Silicon Valley Bank [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	7
Silicon Valley Bank Loan [Member]
Long-term Debt, Fair Value		$ 6.8	$ 7
Payments of Debt Issuance Costs	$ 0.1
Silicon Valley Bank Loan [Member] | Term Loan, First Tranche [Member]
Debt Instrument, Face Amount	$ 7
Debt Instrument, Interest Rate, Stated Percentage	6.75%
Additional Fee Percentage	5.00%
Silicon Valley Bank Loan [Member] | Term Loan, First Tranche [Member] | Minimum [Member]
Prepayment Fee Rate	1.00%
Silicon Valley Bank Loan [Member] | Term Loan, First Tranche [Member] | Maximum [Member]
Prepayment Fee Rate	3.00%
Silicon Valley Bank Loan [Member] | Term Loan, Second Tranche [Member]
Debt Instrument, Face Amount if Company Meets Requirements, Maximum	$ 3
Debt Instrument, Proceeds from Sale of Common Shares Required for Debt Issuance	$ 20

Note 8 - Promissory Notes - Fut

Note 8 - Promissory Notes - Future Contractual and Final Fee Payments (Details) $ in Thousands	Sep. 30, 2018USD ($)
2,019	$ 2,100
2,020	2,800
2,021	2,450
Total	$ 7,350

Note 8 - Promissory Notes - Act

Note 8 - Promissory Notes - Actual Interest Expense and Amortization of Debt Discount (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Simple interest	$ 121	$ 25	$ 358	$ 25
Accretion of debt discount	38	7	113	7
Amortization of promissory note issuance costs	14	3	43	3
Total	$ 173	$ 35	$ 514	$ 35

Note 9 - Revenue for License _2

Note 9 - Revenue for License Agreement (Details Textual) - Kissei Pharmaceuticals Co, Ltd. [Member] - USD ($) $ in Millions	1 Months Ended	9 Months Ended	12 Months Ended
	Apr. 30, 2010	Sep. 30, 2018	Dec. 31, 2013	Dec. 31, 2010
Upfront Payment Related to Licensing Agreement	$ 3
Non-refundable Milestone Payments Entitled to Receive		$ 72
Revenue Recognition, Milestone Method, Revenue Recognized			$ 5	$ 3
Minimum [Member]
Percentage of Royalty Payable under Agreement		20.00%
Maximum [Member]
Percentage of Royalty Payable under Agreement		29.00%
Benign Prostate Hyperplasia [Member]
Non-refundable Milestone Payments Entitled to Receive		$ 17
Benign Prostate Hyperplasia [Member] | Development Activities [Member]
Non-refundable Milestone Payments Entitled to Receive		5
Benign Prostate Hyperplasia [Member] | Regulatory Approvals [Member]
Non-refundable Milestone Payments Entitled to Receive		7
Benign Prostate Hyperplasia [Member] | Gross Sale Targets [Member]
Non-refundable Milestone Payments Entitled to Receive		5
Prostate Cancer [Member]
Non-refundable Milestone Payments Entitled to Receive		21
Prostate Cancer [Member] | Development Activities [Member]
Non-refundable Milestone Payments Entitled to Receive		7
Prostate Cancer [Member] | Regulatory Approvals [Member]
Non-refundable Milestone Payments Entitled to Receive		7
Prostate Cancer [Member] | Gross Sale Targets [Member]
Non-refundable Milestone Payments Entitled to Receive		7
Prostatitis and Other Diseases of Prostate [Member]
Non-refundable Milestone Payments Entitled to Receive		21
Prostatitis and Other Diseases of Prostate [Member] | Development Activities [Member]
Non-refundable Milestone Payments Entitled to Receive		7
Prostatitis and Other Diseases of Prostate [Member] | Regulatory Approvals [Member]
Non-refundable Milestone Payments Entitled to Receive		7
Prostatitis and Other Diseases of Prostate [Member] | Gross Sale Targets [Member]
Non-refundable Milestone Payments Entitled to Receive		7
Milestones Not Associated with Indication [Member]
Non-refundable Milestone Payments Entitled to Receive		13
Milestones Not Associated with Indication [Member] | Regulatory Approvals [Member]
Non-refundable Milestone Payments Entitled to Receive		5
Milestones Not Associated with Indication [Member] | Gross Sale Targets [Member]
Non-refundable Milestone Payments Entitled to Receive		$ 8

Note 10 - Stock-based Compens_3

Note 10 - Stock-based Compensation Plan (Details Textual) $ in Millions	9 Months Ended
	Sep. 30, 2018USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares	71,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $	$ 0.4
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	300 days

Note 10 - Stock-based Compens_4

Note 10 - Stock-based Compensation Plan - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock-based compensation expense	$ 257	$ 461	$ 677	$ 1,328
Research and Development Expense [Member]
Stock-based compensation expense	38	121	142	376
General and Administrative Expense [Member]
Stock-based compensation expense	$ 219	$ 340	$ 535	$ 952

Note 10 - Stock-based Compens_5

Note 10 - Stock-based Compensation Plan - Stock Option Activity (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Options outstanding (in shares) | shares	2,931
Weighted average exercise price - options outstanding (in dollars per share) | $ / shares	$ 3.10
Options granted (in shares) | shares	80
Weighted average exercise price - options granted (in dollars per share) | $ / shares	$ 2.91
Options expired (in shares) | shares	(71)
Weighted average exercise price - options expired (in dollars per share) | $ / shares	$ 13.16
Options outstanding (in shares) | shares	2,940
Weighted average exercise price - options outstanding (in dollars per share) | $ / shares	$ 2.85

Note 10 - Stock-based Compens_6

Note 10 - Stock-based Compensation Plan - Fair Value of Options Granted (Details)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Expected life of the option term (years) (Year)	4 years 255 days	4 years 36 days
Risk-free interest rate	2.67%	1.61%
Dividend rate	0.00%	0.00%
Volatility	126.20%	144.80%

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Purchase Commitment, Estimated Penalties	$ 1		$ 1
Research and Development Expense [Member]
Purchase Commitment, Penalty Expense	$ 0.7	$ 0.1	$ 4.3	$ 0.2
Minimum [Member]
Purchase Commitment, Percentage of Penalty to Pay, If Scheduled Activities Are Canceled Without Notice	50.00%		50.00%
Maximum [Member]
Purchase Commitment, Percentage of Penalty to Pay, If Scheduled Activities Are Canceled Without Notice	100.00%		100.00%